Drug intelligence / Profile preview

Gaviscon

Development stage
Unknown
Lead developer
Reckitt Benckiser Healthcare
Modality
Small Molecules
Administration
Oral
01

Overview

Gaviscon is a widely used over-the-counter medication for the treatment of gastroesophageal reflux disease (GERD), heartburn, and acid indigestion. Its primary mechanism of action distinguishes it from simple antacids; it contains an alginate (typically sodium alginate) which, upon contact with gastric acid, precipitates into a viscous, pH-neutral gel. This gel, often called a "raft," floats on top of the stomach contents, creating a physical barrier that prevents the reflux of acid and pepsin into the esophagus. Most formulations also include antacids like sodium bicarbonate or calcium carbonate, which neutralize existing stomach acid and provide carbon dioxide bubbles that help the alginate raft float. While the specific active ingredients can vary by region—with the UK version emphasizing the alginate raft and some US versions utilizing aluminum hydroxide and magnesium carbonate—the brand is synonymous with rapid symptomatic relief of reflux symptoms.

Brand names
GavisconGaviscon AdvanceGaviscon Double ActionGaviscon Extra StrengthGaviscon Infant
Other names
Alginate antacid
02

Targets

Gastroesophageal junction acid pocket

Beyond the preview

Go deeper on Gaviscon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gaviscon.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call